Previously, Duramed, a subsidiary of Barr Pharmaceuticals, has announced that the FDA has accepted for review its biologics license application for the vaccines. The vaccines will be used by the US Department of Defense for administration to military personnel.
David Dodd, president, CEO and chairman of BioReliance, said: “We are pleased to partner with Barr in meeting this significant unmet medical need. We look forward to working with them on this program and to developing a long-lasting mutually beneficial relationship.”